The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

The FDA and the maker of the popular diabetes and weight loss drug Ozempic are warning people not to use counterfeit semaglutide 1.0 milligrams — the Ozempic injection — found in the U.S. drug supply ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Novo Nordisk’s Vikrant Shrotriya on accelerating Wegovy’s launch, pricing strategy, and building long-term obesity care infrastructure in India ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Novo Nordisk’s strong intangible assets in diabetes and related cardiometabolic diseases like obesity give the firm a wide economic moat that will shield profitability for the long run.

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron.